Vitamin D status and its relationship with bone mineral density in a healthy Iranian population

Khashayar, Patricia; Meybodi, Hamid Reza Aghaei; Hemami, Mohsen Rezai; Keshtkar, Abbasali; Dimai, Hans Peter; Larijani, Bagher

doi:10.1016/j.rboe.2015.09.011

Cited by 13 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, data on SAA and postmenopausal osteoporosis are insufficient. As far as we know, there is only one study and it did not consider the association between SAA level and BMD [ 26 ].In contrast to our results, there are some reports in favor of the association between BMD and serum vitamin D [ 8 , 9 , 36 ] or hs-CRP [ 37 ] in osteoporosis, but the data are inadequate with respect to postmenopausal osteoporosis.To sum up, it is difficult to confirm the protective role of vitamin D (alone) and its immune-regulatory mechanism of action in osteoporosis and its related conditions, due to diversity in studies and contradictive results. These differences might have been influenced by several factors.…”

Section: Discussioncontrasting

confidence: 99%

Circulating Serum Amyloid A, hs-CRP and Vitamin D Levels in Postmenopausal Osteoporosis

Safari

Borhani‐Haghighi

Dianatpour

et al. 2019

GMJ

View full text Add to dashboard Cite

Background: Both vitamin D and inflammation were investigated as important players in the pathogenesis of postmenopausal osteoporosis. This study compared vitamin D, inflammatory the biomarkers serum levels and their association with bone mineral density (BMD) in case and control groups to evaluate the possible immune-regulatory effect of vitamin D in this population. Materials and Methods: Participants in post-menopausal age, were categorized to 44 osteoporotic vs. 44 healthy aged-matched women according to WHO criteria. Total BMD, T- scores, Z-scores as well as fracture risk were measured in both groups, using Hologic system Dual-energy X-ray absorptiometry (DEXA). Serum 25-OH vitamin D, high sensitive CRP (hs-CRP) and serum amyloid A (SAA) were compared between groups. The association between serum biomarkers level and BMD were also investigated. The same evaluations were performed for vitamin D deficient (<20 ng/mL) and non-deficient (≥20 ng/mL) subgroups. Results: Vitamin D deficiency was higher in the osteoporotic group (32.6%) in comparison with the control group (25.6%), but the differences were not significant (P=0.47). There were no significant differences in serum levels of hs-CRP and SAA (P=0.83 and P=0.39) as well. No significant association between serum inflammatory biomarkers, vitamin D, and BMD were detected (P≥0.05). The results were the same for vitamin D deficient and non-deficient subgroups (P≥0.05). Conclusion: In the current study, the beneficial effects of vitamin D as a result of its immune-regulatory mechanisms was not reached. Larger scale studies might pave the way to define vitamin D benefits in postmenopausal osteoporosis. [GMJ.2019;8:e1548]

show abstract

Section: Discussioncontrasting

confidence: 99%

Circulating Serum Amyloid A, hs-CRP and Vitamin D Levels in Postmenopausal Osteoporosis

Safari

Borhani‐Haghighi

Dianatpour

et al. 2019

GMJ

View full text Add to dashboard Cite

show abstract

“…Moreira et al evaluated healthy men in Brazil and authors found a high prevalence of vitamin D deficiency and its relation to increased osteoporosis (28). Khashayar et al reported significant correlation of vitamin D deficiency and BMD in healthy Iranian men (29). Sundh et al emphasized that serum vitamin D is associated with higher cortical porosity in elderly men (30).…”

Section: Resultsmentioning

confidence: 99%

Hip Fracture Surgery in Patients Older than 90 Years: Evaluation of Factors that Affect 30-Day Mortality in a Particularly Risky Group

Daşar¹

2018

tjgeri

View full text Add to dashboard Cite

Introduction: Osteoporosis in men is often underdiagnosed and neglected compared to postmenopausal women. Major risk factors should be determined to prevent this disease, which has potential risk of mortality and morbidity for elder men. This study's purpose was to determine the risk factors for osteoporosis and osteopenia in male patients aged >60 years.Materials and Method: Between January 2015 and June 2017, male patients aged >60 years admitted to our centers who underwent dual energy x-ray absorptiometry (DXA) were included in this retrospective study. Patients' age, body mass index, site of residence (village/ city), smoking status, and systemic diseases were examined through our records. Patients were divided into control, osteopenia, and osteoporosis groups according to DXA measurements. Serum vitamin D measurements also were evaluated. Multivariate analysis was performed to determine major risk factors for osteoporosis and osteopenia.Results: Compared with the control group, patients in the group categorized as having osteoporosis or osteopenia had a significantly lower body mass index and more commonly resided in the city (p<0.001 and p<0.005, respectively). Serum vitamin D levels were significantly lower in the osteoporosis and osteopenia groups than in the control group (p=0.001). According to multivariate analysis, insufficient or deficient serum vitamin D levels were determined to be a major risk factor for osteoporosis and osteopenia (p=0.001).Conclusion: According to our results, men aged >60 years with deficient serum vitamin D levels (<20 ng/mL) were six times more likely to have osteopenia and 80 times more likely to have osteoporosis.Keywords: Osteoporosis; Bone diseases, Metabolic; Bone density; Risk factors; Vitamin D Giriş: Erkeklerde osteoporoz postmenopozal kadınlara kıyasla çoğunlukla az tanı alır ve ihmal edilir. Yaşlı erkeklerde potansiyel mortalite ve morbidite riski taşıyan bu hastalığı önlemek için başlıca risk faktörleri belirlenmelidir. Bu çalışmanın amacı, 60 yaş üzerindeki erkek hastalarda osteoporoz ve osteopeni için risk faktörlerini belirlemektir.Gereç ve Yöntem: Ocak 2015-Haziran 2017 tarihleri arasında merkezlerimize başvuran ve Dual Enerji X-ray Absorptiometri (DXA) ölçümleri yapılan 60 yaş üzeri erkek hastalar bu retrospektif çalışmaya dahil edildi. Hastaların yaşı, beden kütle indeksi (BKİ), yerleşim yeri (köy-şehir), sigara içme durumu ve sistemik hastalıkları kayıtlarımızdan incelendi. Hastalar DXA ölçümlerine göre kontrol, osteopeni ve osteoporoz olarak 3 gruba ayrıldı. Hastaların serum vitamin D ölçümleri de değerlendirildi. Osteoporoz ve osteopeni için temel risk faktörlerini belirlemek için çok değişkenli analiz uygulandı.Bulgular: Kontrol grubuyla karşılaştırıldığında, osteoporoz veya osteopeni grubundaki hastalarda VKİ anlamlı derecede düşüktü ve bunlar daha çok şehirde yerleşikti (sırasıyla p<0.001 ve 0.005). Serum vitamin D seviyeleri osteoporoz ve osteopeni gruplarında kontrol grubuna göre anlamlı düşüktü (p=0.001). Çok değişkenli analize göre, yetersiz veya ...

show abstract

“…Roux et al described a positive association between 25(OH)D and L-BMD or femoral neck BMD in postmenopausal women treated with ALN 19. In Malaysian RA female patients, serum 25(OH)D levels were low compared with those in healthy controls, with no associations between 25(OH)D and BMD,20 while a negative relationship was identified between 25(OH)D levels and BMD in both sexes in a healthy Iranian population 21. In Palestinian postmenopausal OP patients, a positive correlation was reported between 25(OH)D and L-BMD 22.…”

Section: Discussionmentioning

confidence: 99%

Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis

Suzuki

Nakamura

Kato

2018

TCRM

View full text Add to dashboard Cite

BackgroundThis 3-year retrospective study compared the outcomes of bisphosphonate-pretreated denosumab therapy with or without vitamin D and calcium supplementation in postmenopausal osteoporosis (OP) patients with rheumatoid arthritis (RA).Materials and methodsFifty-eight patients under long-term denosumab treatment were divided into groups without (denosumab group; 31 cases) or with (combination group; 27 cases) vitamin D and calcium supplementation. The bone markers of BAP, TRACP-5b, and urinary NTX were measured at baseline and every year for 3 years. We also evaluated bone mineral density (BMD) of the lumbar 1–4 vertebrae (L-BMD) and bilateral total hips (H-BMD) at the same time points.ResultsThere were no significant differences in the percent changes of serum albumin-corrected calcium between the groups. The percent change in TRACP-5b was significantly higher in the combination group at 2 years. Serum 25-hydroxyvitamin D status was persistently high during therapy in both groups, with significant percent increases over baseline at 2 and 6 months in both groups and at 24 months in the combination group. The percent increase from baseline of serum zinc was significantly higher at 3 years in the combination group over the denosumab group. L-BMD and H-BMD were significantly increased at every time point for 3 years vs pretreatment levels in both groups and were significantly higher in the combination group at all time points.ConclusionCompared with denosumab monotherapy, the combination group displayed significantly increased serum zinc, L-BMD, and H-BMD at 3 years in OP patients with RA. Thus, calcium and vitamin D supplementation may be beneficial to enhance BMD gains, but not necessarily 25-hydroxyvitamin D status, in patients with OP and RA under denosumab.

show abstract

Vitamin D status and its relationship with bone mineral density in a healthy Iranian population

Cited by 13 publications

References 21 publications

Circulating Serum Amyloid A, hs-CRP and Vitamin D Levels in Postmenopausal Osteoporosis

Circulating Serum Amyloid A, hs-CRP and Vitamin D Levels in Postmenopausal Osteoporosis

Hip Fracture Surgery in Patients Older than 90 Years: Evaluation of Factors that Affect 30-Day Mortality in a Particularly Risky Group

Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis

Contact Info

Product

Resources

About